Spruce Biosciences

SPRB on Nasdaq. Pharmaceutical preparations. Market value $124m.

Watch this stockFree. We tell you when something changes.

Figures from the annual report for the year ended 31 December 2025.

Cash flow or capital spending isn't reported, so free cash flow is unknown.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
n/a

We could not compute this from the filings.

Price to profit
annual report to December 2025
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 40 of 100. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.

Five years of cash, in billions

-0.0
-0.0
-0.0
-0.1
n/a
20212022202320242025
Revenue
n/a$0$10m$5m$0
Operating margin
n/an/a-515.3%-1143.4%n/a
Debt to equity
0.040.080.050.060.00
Shares outstanding
0.02bn0.04bn0.04bn0.00bn0.00bn

Health checks

  • Free cash flow positive0 of 4 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)3 of 8 checks we could run
  • Profit backed by cash (accruals)No
  • Debt0.00× equity
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesYes, 88% fewer since 2021

Dates

Next results (estimated)
n/a
Last annual report (10-K)
9 March 2026
Next quarterly (estimated, 10-Q)
8 February 2027

Who owns it

None of the long-term investors we follow own it. 64 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

14 investors own more than 5%.

  • Orin Hirschman
    Passive investor
    at least 9.1%
    (filed with 1 related holder)
    Since 30 June 2026
  • BlackRock, Inc.
    Passive investor
    6.8%
    Since 30 June 2026
  • Boone Peter David Mr
    Passive investor
    6.4%
    Since 21 November 2025
  • Integrated Core Strategies (US) LLC
    Passive investor
    at least 5.8%−3.8 pts
    (filed with 3 related holders)
    Since 30 June 2026
  • OrbiMed Advisors LLC
    Passive investor
    at least 5.6%+0.8 pts
    (filed with 2 related holders)
    Since 30 September 2026
  • 5.1%
    Since 30 June 2026
  • Ikarian Capital, LLC
    Passive investor
    at least 4.8%−6.6 pts
    (filed with 1 related holder)
    Since 30 April 2026
  • The Carlyle Group Inc.
    Passive investor
    at least 4.7%
    (filed with 9 related holders)
    Since 18 February 2026
    What they said

    Item 4 of the Schedule 13D is hereby amended as follows: Bali Muralidhar, who represented Abingworth Bioventures VII LP on the Issuer's board of directors, resigned as a director in October 2025.

    Read the filing
  • at least 4.5%−1.3 pts
    (filed with 2 related holders)
    Since 31 March 2026
  • John P. McKearn, Ph.D.
    Passive investor
    at least 4.2%
    (filed with 10 related holders)
    Since 7 January 2025
    What they said

    No change.

    Read the filing
  • at least 3.6%−1.9 pts
    (filed with 2 related holders)
    Since 31 March 2026
  • HealthCap VIII, L.P.
    Passive investor
    at least 3.4%
    (filed with 1 related holder)
    Since 7 October 2025
  • at least 2.5%−2.9 pts
    (filed with 1 related holder)
    Since 30 June 2026
  • Kenneth Griffin
    Passive investor
    at least 1.9%−3.2 pts
    (filed with 6 related holders)
    Since 30 June 2026
  • Sold down below 5%
    Since 31 March 2026
  • Sold down below 5%
    Since 22 April 2026
  • Radoff Family Foundation
    Passive investor
    Sold down below 5%
    Since 30 June 2025
  • Sold down below 5%
    Since 3 July 2025
  • Rosalind Advisors, Inc.
    Passive investor
    Sold down below 5%
    Since 31 December 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought or sold on the open market in the last 12 months.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Spruce Biosciences’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 9 Mar 2026, plus the 10-Q filed 9 Nov 2026 and 7 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern for at least 12 months following the issuance date of these condensed consolidated financial statements.”
    Show the full paragraph
    The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. Without alternative financing or proceeds from other strategic alternatives, the Company believes that based on its current operating plan, its cash and cash equivalents of $ 87.7 million as of September 30, 2026 will be insufficient to fund its planned operations and debt obligations for at least 12 months following the issuance date of these condensed consolidated financial statements. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern for at least 12 months following the issuance date of these condensed consolidated financial statements. In addition, the Avenue Loan Agreement contains a subjective acceleration clause. If Avenue were to declare an event of default, including on the basis of a material adverse effect, the outstanding obligations under the Avenue Loans could become immediately due and payable.

    From the 10-Q filed 9 November 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.